Cuirong Zhao

515 total citations
23 papers, 435 citations indexed

About

Cuirong Zhao is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Cuirong Zhao has authored 23 papers receiving a total of 435 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Molecular Biology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Cuirong Zhao's work include Peptidase Inhibition and Analysis (5 papers), Cancer Treatment and Pharmacology (4 papers) and Cancer therapeutics and mechanisms (4 papers). Cuirong Zhao is often cited by papers focused on Peptidase Inhibition and Analysis (5 papers), Cancer Treatment and Pharmacology (4 papers) and Cancer therapeutics and mechanisms (4 papers). Cuirong Zhao collaborates with scholars based in China, Canada and Japan. Cuirong Zhao's co-authors include Xian‐Jun Qu, Qian Wang, Zu‐Hua Gao, Xue Xia, Hong‐Xiang Lou, Huiping Liu, Cuicui Sun, Chao Wang, Shu‐Xiang Cui and Yanna Cheng and has published in prestigious journals such as PLoS ONE, European Journal of Pharmacology and European Journal of Cancer.

In The Last Decade

Cuirong Zhao

23 papers receiving 432 citations

Peers

Cuirong Zhao
Catherine Higgins United Kingdom
Yu‐Jen Yu Taiwan
Ayako Honda Japan
John E. Brown United Kingdom
Fay Habens United Kingdom
Kevin Yang United States
Yuan He China
Chang‐Ho Ahn United States
Coral Omene United States
Ansam Sinjab United States
Catherine Higgins United Kingdom
Cuirong Zhao
Citations per year, relative to Cuirong Zhao Cuirong Zhao (= 1×) peers Catherine Higgins

Countries citing papers authored by Cuirong Zhao

Since Specialization
Citations

This map shows the geographic impact of Cuirong Zhao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cuirong Zhao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cuirong Zhao more than expected).

Fields of papers citing papers by Cuirong Zhao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cuirong Zhao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cuirong Zhao. The network helps show where Cuirong Zhao may publish in the future.

Co-authorship network of co-authors of Cuirong Zhao

This figure shows the co-authorship network connecting the top 25 collaborators of Cuirong Zhao. A scholar is included among the top collaborators of Cuirong Zhao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cuirong Zhao. Cuirong Zhao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Zhang, Rui, et al.. (2022). Ginkgolide C Alleviates Acute Lung Injury Caused by Paraquat Poisoning via Regulating the Nrf2 and NF‐κB Signaling Pathways. Oxidative Medicine and Cellular Longevity. 2022(1). 7832983–7832983. 9 indexed citations
3.
Fang, Yong, Cuirong Zhao, Cheng Huang, & Liang Liu. (2020). SankeyVis: Visualizing active relationship from emails based on multiple dimensions and topic classification methods. Forensic Science International Digital Investigation. 35. 300981–300981. 7 indexed citations
4.
Chu, Jiahui, Cuirong Zhao, Zhiyu Song, et al.. (2014). 1082-39, an analogue of sorafenib, inhibited human cancer cell growth more potently than sorafenib. Biomedicine & Pharmacotherapy. 68(3). 335–341. 8 indexed citations
5.
Zhao, Cuirong, et al.. (2014). A novel anticancer diarylurea derivative HL-40 as a multi-kinases inhibitor with good pharmacokinetics in Wistar rats. Biomedicine & Pharmacotherapy. 69. 255–259. 6 indexed citations
6.
Zhao, Cuirong, Ruiqi Wang, Gang Li, et al.. (2013). Synthesis of indazole based diarylurea derivatives and their antiproliferative activity against tumor cell lines. Bioorganic & Medicinal Chemistry Letters. 23(7). 1989–1992. 36 indexed citations
7.
Zhao, Cuirong, Yuanyuan Li, Ruiqi Wang, et al.. (2013). Pharmacokinetics and metabolism of SL-01, a prodrug of gemcitabine, in rats. Cancer Chemotherapy and Pharmacology. 71(6). 1541–1550. 7 indexed citations
8.
Zhao, Cuirong, Xiaoxia Xue, Gang Li, et al.. (2012). Synthesis and Biological Evaluation of Oral Prodrugs Based on the Structure of Gemcitabine. Chemical Biology & Drug Design. 80(3). 479–488. 6 indexed citations
9.
Zhao, Cuirong, Bin Yue, Huiping Liu, et al.. (2012). SL-01, an oral gemcitabine derivative, inhibited human cancer growth more potently than gemcitabine. Toxicology and Applied Pharmacology. 262(3). 293–300. 6 indexed citations
10.
Liu, Huiping, Zu‐Hua Gao, Shu‐Xiang Cui, et al.. (2012). Inhibition of Intestinal Adenoma Formation in APCMin/+ Mice by Riccardin D, a Natural Product Derived from Liverwort Plant Dumortiera hirsuta. PLoS ONE. 7(3). e33243–e33243. 21 indexed citations
11.
Xia, Xue, Cuicui Sun, Huiping Liu, et al.. (2012). Inhibitory effect of riccardin D on growth of human non-small cell lung cancer: In vitro and in vivo studies. Lung Cancer. 76(3). 300–308. 27 indexed citations
12.
Yue, Bin, Yusheng Zhang, Huimin Xu, et al.. (2012). Riccardin D-26, a synthesized macrocyclic bisbibenzyl compound, inhibits human hepatocellular carcinoma growth through induction of apoptosis in p53-dependent way. Cancer Letters. 328(1). 104–113. 15 indexed citations
13.
Yue, Bin, Cuirong Zhao, Huimin Xu, et al.. (2012). Riccardin D-26, a synthesized macrocyclic bisbibenzyl compound, inhibits human oral squamous carcinoma cells KB and KB/VCR: In vitro and in vivo studies. Biochimica et Biophysica Acta (BBA) - General Subjects. 1830(1). 2194–2203. 10 indexed citations
14.
Pan, Yue, Zu‐Hua Gao, Xue Xia, et al.. (2011). Des-γ-carboxyl prothrombin induces matrix metalloproteinase activity in hepatocellular carcinoma cells by involving the ERK1/2 MAPK signalling pathway. European Journal of Cancer. 47(7). 1115–1124. 36 indexed citations
15.
Sun, Cuicui, Xue Xia, Yanna Cheng, et al.. (2011). Inhibition of angiogenesis involves in anticancer activity of riccardin D, a macrocyclic bisbibenzyl, in human lung carcinoma. European Journal of Pharmacology. 667(1-3). 136–143. 35 indexed citations
16.
Liu, Huiping, Zu‐Hua Gao, Shu‐Xiang Cui, et al.. (2011). Haishengsu, a Protein from Shellfish Tegillarca L. granosa, Inhibits the Growth and the Activity of Matrix Metalloproteinases-2 and -9 in Human Lung Carcinoma. Food Biophysics. 6(3). 390–396. 6 indexed citations
17.
Gao, Jianjun, Zu‐Hua Gao, Cuirong Zhao, et al.. (2010). LYP, a novel bestatin derivative, inhibits cell growth and suppresses APN/CD13 activity in human ovarian carcinoma cells more potently than bestatin. Investigational New Drugs. 29(4). 574–582. 19 indexed citations
18.
Xia, Xue, Xian‐Jun Qu, Zu‐Hua Gao, et al.. (2010). Riccardin D, a novel macrocyclic bisbibenzyl, induces apoptosis of human leukemia cells by targeting DNA topoisomerase II. Investigational New Drugs. 30(1). 212–222. 40 indexed citations
19.
Cui, Shu‐Xiang, Xian‐Jun Qu, Zu‐Hua Gao, et al.. (2009). Targeting aminopeptidase N (APN/CD13) with cyclic-imide peptidomimetics derivative CIP-13F inhibits the growth of human ovarian carcinoma cells. Cancer Letters. 292(2). 153–162. 41 indexed citations
20.
Zhang, Xiao-Fan, Julia Li Zhong, Wei Liu, et al.. (2009). N3-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU. Cancer Chemotherapy and Pharmacology. 66(1). 11–19. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Catherine Higgins Breakdown of academic impact, for papers by Yu‐Jen Yu Breakdown of academic impact, for papers by Ayako Honda Breakdown of academic impact, for papers by John E. Brown Breakdown of academic impact, for papers by Fay Habens Breakdown of academic impact, for papers by Kevin Yang Breakdown of academic impact, for papers by Yuan He Breakdown of academic impact, for papers by Chang‐Ho Ahn Breakdown of academic impact, for papers by Coral Omene Breakdown of academic impact, for papers by Ansam Sinjab
Rankless by CCL
2026